» Articles » PMID: 28864555

Distinct Signaling Patterns of Allosteric Antagonism at the P2Y Receptor

Overview
Journal Mol Pharmacol
Date 2017 Sep 3
PMID 28864555
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Traditionally, G protein-coupled receptor antagonists are classified as competitive or noncompetitive and surmountable or insurmountable based on functional antagonism. P2Y receptor (P2YR) structures showed two antagonists binding to two spatially distinct sites: nucleotide MRS2500 (orthosteric, contacting the helical bundle) and urea BPTU (allosteric, on the external receptor surface). However, the nature of their P2YR antagonism has not been characterized. Here we characterized BPTU antagonism at various signaling pathways activated by structurally diverse agonists. BPTU rightward shifted the concentration-response curves of both 2-methylthioadenosine 5'-diphosphate trisodium salt and MRS2365 (5'-diphosphates) in some signaling events, such as extracellular signal-regulated kinase 1/2 and label free, in a parallel manner without affecting the maximum agonist effect (E) but antagonized insurmountably (suppressed agonist E) in signaling events such as guanosine 5'-3--(thio)triphosphate binding and -arrestin2 recruitment. However, with dinucleotide Ap4A as an agonist, BPTU suppressed the E insurmountably in all signaling pathways. By comparison, MRS2500 behaved as surmountable antagonist rightward-shifting concentration-response curves of all three agonists in a parallel manner for all signaling pathways measured. Thus, we demonstrated a previously undocumented phenomenon that P2YR antagonism patterns could vary in different signaling pathways, which could be related to conformational selection, signaling amplification, and probe dependence. This phenomenon may apply generally to other receptors considering that antagonism by a specific ligand is often not compared at multiple signaling pathways. Thus, antagonism can be surmountable or insurmountable depending on the signaling pathways measured and the agonists used, which should be of broad relevance to drug discovery and disease treatment.

Citing Articles

A adenosine receptor-triggered intracellular calcium mobilization: Cell type-dependent involvement of G, G, G proteins and protein kinase C.

Gao Z, Gao R, Meyer C, Jacobson K Purinergic Signal. 2025; .

PMID: 39934472 DOI: 10.1007/s11302-025-10070-1.


A2B adenosine receptor-triggered intracellular calcium mobilization: Cell type-dependent involvement of Gi, Gq, Gs proteins and protein kinase C.

Gao Z, Gao R, Meyer C, Jacobson K Res Sq. 2024; .

PMID: 39711556 PMC: 11661376. DOI: 10.21203/rs.3.rs-5442142/v1.


Design, synthesis, biological evaluation, kinetic studies and molecular modeling of imidazo-isoxazole derivatives targeting both α-amylase and α-glucosidase inhibitors.

AlRashidi E, Ghannay S, Albadri A, Abid M, Kadri A, Aouadi K Heliyon. 2024; 10(20):e38376.

PMID: 39640664 PMC: 11619978. DOI: 10.1016/j.heliyon.2024.e38376.


Pharmacological characterization of P2Y receptor subtypes - an update.

von Kugelgen I Purinergic Signal. 2023; 20(2):99-108.

PMID: 37697211 PMC: 10997570. DOI: 10.1007/s11302-023-09963-w.


Exploring bias in platelet P2Y signalling: Host defence versus haemostasis.

Pan D, Ladds G, Rahman K, Pitchford S Br J Pharmacol. 2023; 181(4):580-592.

PMID: 37442808 PMC: 10952580. DOI: 10.1111/bph.16191.


References
1.
Kenakin T . What is pharmacological 'affinity'? Relevance to biased agonism and antagonism. Trends Pharmacol Sci. 2014; 35(9):434-41. DOI: 10.1016/j.tips.2014.06.003. View

2.
Guo D, Hillger J, IJzerman A, Heitman L . Drug-target residence time--a case for G protein-coupled receptors. Med Res Rev. 2014; 34(4):856-92. DOI: 10.1002/med.21307. View

3.
Azzi M, Charest P, Angers S, Rousseau G, Kohout T, Bouvier M . Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci U S A. 2003; 100(20):11406-11. PMC: 208770. DOI: 10.1073/pnas.1936664100. View

4.
Palmer R, Boyer J, Schachter J, Nicholas R, Harden T . Agonist action of adenosine triphosphates at the human P2Y1 receptor. Mol Pharmacol. 1998; 54(6):1118-23. View

5.
Kendall R, Lee M, Pleasant D, Robinson K, Kuppuswamy D, McDermott P . Arrestin-dependent angiotensin AT1 receptor signaling regulates Akt and mTor-mediated protein synthesis. J Biol Chem. 2014; 289(38):26155-26166. PMC: 4176252. DOI: 10.1074/jbc.M114.595728. View